Simon Property Group Inc
Change company Symbol lookup
Select an option...
SPG Simon Property Group Inc
JNJ Johnson & Johnson
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
WMT WALMART STORES INC
BROG Brooge Holdings Ltd
EMRAF Emera Inc
PPL PPL Corp
PG Procter & Gamble Co
CLOU Global X Cloud Computing ETF Global X Cloud Computing ETF
GDRX Goodrx Holdings Inc
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Value
Company profile

Simon Property Group, Inc. is a self-administered and self-managed real estate investment trust (REIT). The Company owns, develops and manages retail real estate properties, which consist primarily of malls, Premium Outlets and The Mills. Simon Property Group, L.P. (Operating Partnership), is the Company's partnership subsidiary that owns all of its real estate properties and other assets. As of December 31, 2016, the Company owned or held an interest in 206 income-producing properties in the United States, which consisted of 108 malls, 67 Premium Outlets, 14 Mills, four lifestyle centers, and 13 other retail properties in 37 states and Puerto Rico. As of December 31, 2016, it had redevelopment and expansion projects, including the addition of anchors, big box tenants, and restaurants, underway at 27 properties in the United States and it had one outlet and one other retail project under development.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$82.57
Day's Change
-2.98 (-3.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
86.90
Day's Low
82.40
Volume
(Light)
Volume:
6,983,693

10-day average volume:
8,774,595
6,983,693

Regeneron's stock rallies after it announces EUA request for antibody treatment

8:31 am ET October 8, 2020 (MarketWatch)
Print

Shares of Regeneron Pharmaceuticals Inc. (REGN) were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody treatment. The therapy was prescribed to President Donald Trump last week as part of his COVID-19 treatment plan; on Wednesday, in a video, Trump called it a "cure." (http://www.marketwatch.com/story/trump-calls-contracting-coronavirus-blessing-from-god-in-latest-video-2020-10-07) (He was also prescribe (http://www.marketwatch.com/story/trumps-coronavirus-diagnosis-underscores-lack-of-treatment-options-for-people-with-mild-forms-of-covid-19-2020-10-02)d Gilead Sciences Inc.'s (GILD) remdesivir and the steroid dexamethasone.) Regeneron's announcement to file for an emergency use authorization (EUA) came the same day that Eli Lilly & Co. (LLY), which is also developing an antibody treatment for mild to moderate COVID-19 patients, announced Wednesday morning it had requested an EUA (http://www.marketwatch.com/story/lilly-submits-authorization-request-to-fda-for-antibody-based-covid-19-therapy-2020-10-07). Regeneron's stock is up 57.6% so far this year. The S&P 500 , in comparison, has gained 5.8%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 08, 2020 08:31 ET (12:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.